Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of CTSG (cathepsin G) cell factor in preparation of medicaments to treat hepatic failure

A technology for liver failure and cytokines, applied in the fields of molecular medicine, biomedicine, and clinical medicine, which can solve the problems of death of patients and shortage of donor livers.

Inactive Publication Date: 2019-09-06
杭州笙源生物科技有限公司
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But due to a severe shortage of donor livers, a large number of patients died while waiting for a liver transplant

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of CTSG (cathepsin G) cell factor in preparation of medicaments to treat hepatic failure
  • Application of CTSG (cathepsin G) cell factor in preparation of medicaments to treat hepatic failure
  • Application of CTSG (cathepsin G) cell factor in preparation of medicaments to treat hepatic failure

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Embodiment 1: Injection containing CTSG cytokines treats a large animal (young pig) model of liver failure

[0043] Animal model: 30 male Chinese young pigs (8-10 kg) were randomly divided into two groups, 15 in each group. Each young pig was injected with 1.5g / kg of D-gal via the jugular vein to create a liver failure model.

[0044] Test group: CTSG injection was intravenously injected multiple times at fixed time points after D-gal injection, dose: 10ml / kg, twice a day.

[0045] Control group: inject the same amount of normal saline without CTSG.

[0046] Neither the control group nor the experimental group received other drug treatment.

[0047] figure 1 It is a schematic diagram of the survival time curves of the young pigs of the experimental group and the control group, showing the survival rate of the young pigs of the experimental group and the control group. The results showed that the 3-day survival rate of young pigs in the treatment group containing CTS...

Embodiment 2

[0048] Embodiment 2: The lyophilized powder injection containing CTSG cytokine treats the small animal (rat) model of liver failure

[0049] Animal model: 100 male rats (200-250 g) were randomly divided into two groups, 50 in each group. Each rat was intraperitoneally injected with D-gal 1.5g / kg to make a liver failure model. The CTSG lyophilized powder and water for injection are prepared into a suspension.

[0050] Experimental group: 4 ml of CTSG freeze-dried powder suspension was injected intraperitoneally at a fixed time point after D-gal injection, twice a day.

[0051] Control group: inject the same amount of normal saline without CTSG.

[0052] Both the control group and the experimental group received no other drug treatment.

[0053] figure 2 Schematic diagram of the survival time curves of rats in the experimental group and the control group, figure 2 The survival rates of rats in the experimental group and the control group were shown: the results showed tha...

Embodiment 3

[0054]Embodiment 3: The suspension containing CTSG cytokine treats the rabbit model of liver failure

[0055] Animal model: 40 adult male rabbits (2000-2500 g) were randomly divided into two groups, 20 in each group. Each rabbit was intramuscularly injected D-gal 1.5g / kg to make a liver failure model.

[0056] Test group: intramuscular injection of 20 ml of CTSG suspension at fixed time points after D-gal injection, twice a day.

[0057] Control group: inject the same amount of normal saline without CTSG.

[0058] Both the control group and the experimental group received no other drug treatment.

[0059] image 3 It is a schematic diagram of the survival time curves of rabbits in the experimental group and the control group, image 3 The survival rate of the rabbits in the experimental group and the control group is expressed: the results show that the survival rate of the rabbits in the CTSG treatment group is 90% at 1 day, 90% at 7 days, and 90% at 14 days, while the co...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of a CTSG (cathepsin G) cell factor in the preparation of medicaments to treat hepatic failure. Death of mass hepatic cells occurs during the course of hepatic failure; the CTSG cell factor helps overcome the aforementioned problem. CTSG JNK (c-Jun N-terminal kinase) is one of MAPK (mitogen-activated protein kinase) family members; JNK pathway can inhibit apoptosis of hepatic cells by regulating the expression of CTSG. The CTSG cell factor can be applied to the preparation of medicaments to treat hepatic failure to significantly increase biochemical indexesof a patient, reduce bilirubin level, lower aminotransferase, improve the coagulation function, inhibit cell apoptosis, promote the regeneration of hepatic cells and bile duct cells, prevent occurrence of fatal complications, such as massive alimentary tract bleeding, severe hepatic encephalopathy and hepatorenal syndrome, extend the survival time of the patient significantly, and increase the survival rate.

Description

technical field [0001] The invention belongs to the fields of clinical medicine, molecular medicine and biomedicine, and is a new technology for treating liver failure with CTSG cytokine series drugs, specifically, an application of CTSG cytokine in the preparation of medicaments for treating liver failure. Background technique [0002] Liver failure is a kind of disease caused by extensive necrosis of the liver caused by various reasons. Except for orthotopic liver transplantation, there is currently no specific treatment. However, due to the severe shortage of donor livers, a large number of patients died while waiting for liver transplantation. Clarifying the pathogenesis of liver failure and early treatment targeting the mechanism can effectively block the progression of the disease and reduce the mortality rate, which is of great significance to the treatment of liver failure. [0003] Cathepsin G (CTSG), a member of the serine protease family, was first discovered in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/19A61P1/16
CPCA61K38/19A61P1/16
Inventor 李君陈新李江江静
Owner 杭州笙源生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com